These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21417007)

  • 1. [The pattern recognition receptor-mediated immune tolerance is involved in tumor metastasis].
    Hu ZW; Yang HZ
    Sheng Li Ke Xue Jin Zhan; 2010 Feb; 41(1):5-10. PubMed ID: 21417007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cancer immunotherapy. Importance of overcoming immune suppression].
    Malvicini M; Puchulo G; Matar P; Mazzolini G
    Medicina (B Aires); 2010; 70(6):565-70. PubMed ID: 21163748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-host immune interactions and dendritic cell dysfunction.
    Yang L; Carbone DP
    Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen specificity of immune suppression by myeloid-derived suppressor cells.
    Solito S; Bronte V; Mandruzzato S
    J Leukoc Biol; 2011 Jul; 90(1):31-6. PubMed ID: 21486906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.
    Poggi A; Zocchi MR
    Arch Immunol Ther Exp (Warsz); 2006; 54(5):323-33. PubMed ID: 17031467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immune tolerance and active suppression in oncology. Immunological principles and therapeutic options].
    Stremmel C; Klein P; Hohenberger W
    Chirurg; 2002 Mar; 73(3):255-61. PubMed ID: 11963500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immune response and cancer].
    El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
    Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive cells in tumor immune escape and metastasis.
    Liu Y; Cao X
    J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-driven evolution of immunosuppressive networks during malignant progression.
    Kim R; Emi M; Tanabe K; Arihiro K
    Cancer Res; 2006 Jun; 66(11):5527-36. PubMed ID: 16740684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How do tumor stem cells actively escape from host immunosurveillance?
    Qi Y; Li RM; Kong FM; Li H; Yu JP; Ren XB
    Biochem Biophys Res Commun; 2012 Apr; 420(4):699-703. PubMed ID: 22465008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving cancer immunotherapy by targeting tumor-induced immune suppression.
    Stewart TJ; Smyth MJ
    Cancer Metastasis Rev; 2011 Mar; 30(1):125-40. PubMed ID: 21249424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis.
    Dirkx AE; Oude Egbrink MG; Wagstaff J; Griffioen AW
    J Leukoc Biol; 2006 Dec; 80(6):1183-96. PubMed ID: 16997855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tricks tumors use to escape from immune control.
    Whiteside TL
    Oral Oncol; 2009 Oct; 45(10):e119-23. PubMed ID: 19467917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RCAS1, MT, and vimentin as potential markers of tumor microenvironment remodeling.
    Dutsch-Wicherek M
    Am J Reprod Immunol; 2010 Mar; 63(3):181-8. PubMed ID: 20085563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs.
    Whiteside TL; Mandapathil M; Szczepanski M; Szajnik M
    Bull Cancer; 2011 Feb; 98(2):E25-31. PubMed ID: 21339097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capitalizing on the immunogenicity of dying tumor cells.
    Fonseca C; Dranoff G
    Clin Cancer Res; 2008 Mar; 14(6):1603-8. PubMed ID: 18347160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-released microvesicles as vehicles of immunosuppression.
    Valenti R; Huber V; Iero M; Filipazzi P; Parmiani G; Rivoltini L
    Cancer Res; 2007 Apr; 67(7):2912-5. PubMed ID: 17409393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor escape from immune surveillance.
    Costello RT; Gastaut JA; Olive D
    Arch Immunol Ther Exp (Warsz); 1999; 47(2):83-8. PubMed ID: 10202560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escape from immune- and nonimmune-mediated tumor surveillance.
    Malmberg KJ; Ljunggren HG
    Semin Cancer Biol; 2006 Feb; 16(1):16-31. PubMed ID: 16140546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer invasion and resistance: interconnected processes of disease progression and therapy failure.
    Alexander S; Friedl P
    Trends Mol Med; 2012 Jan; 18(1):13-26. PubMed ID: 22177734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.